Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients

Abstract

We identified a low rate of success of vedolizumab in patients with active perianal Crohn's disease, and nearly one third of patients with inactive perianal Crohn's disease had perianal recurrence. Further evaluation is warranted in prospective studies.